Cargando…

Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer

BACKGROUND: The nonreceptor tyrosine kinase Src regulates multiple pathways critical to tumor proliferation, chemoresistance, and epithelial-to-mesenchymal transition. It is robustly activated after acute oxaliplatin exposure and in acquired oxaliplatin resistance in vitro and in vivo, but not after...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kopetz, Scott, Morris, Van K, Parikh, Nila, Overman, Michael J, Jiang, Zhi-Qin, Maru, Dipen, Elvin, Paul, Gallick, Gary
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4167273/ https://www.ncbi.nlm.nih.gov/pubmed/25208577 http://dx.doi.org/10.1186/1471-2407-14-660

Ejemplares similares

Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer
por: Lee, Michael S, et al.
Publicado: (2016)

Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src
por: Perez, Marco, et al.
Publicado: (2016)

Correction: Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src
por: Perez, Marco, et al.
Publicado: (2016)

MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon
por: Raghav, Kanwal, et al.
Publicado: (2016)

Single-cell DNA sequencing reveals a late-dissemination model in metastatic colorectal cancer
por: Leung, Marco L., et al.
Publicado: (2017)

Implications of Intratumor Heterogeneity on Consensus Molecular Subtype (CMS) in Colorectal Cancer
por: Chowdhury, Saikat, et al.
Publicado: (2021)

The Association of Alternate VEGF Ligands with Resistance to Anti-VEGF Therapy in Metastatic Colorectal Cancer
por: Lieu, Christopher H., et al.
Publicado: (2013)

Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin
por: Overman, Michael J., et al.
Publicado: (2016)

Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer
por: Kopetz, Scott, et al.
Publicado: (2015)

Combined Inhibition of IGF-1R/IR and Src Family Kinases Enhances Antitumor Effects in Prostate Cancer by Decreasing Activated Survival Pathways
por: Dayyani, Farshid, et al.
Publicado: (2012)

Recent developments in the treatment of metastatic colorectal cancer
por: Loree, Jonathan M., et al.
Publicado: (2017)

Hepatectomy Followed by Adjuvant Chemotherapy with 3‐Month Capecitabine Plus Oxaliplatin for Colorectal Cancer Liver Metastases
por: Satake, Hironaga, et al.
Publicado: (2021)

Vascular endothelial growth factor receptor-1 mediates migration of human colorectal carcinoma cells by activation of Src family kinases
por: Lesslie, D P, et al.
Publicado: (2006)

Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly
por: Aparicio, T, et al.
Publicado: (2003)

Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly
por: Alliot, C, et al.
Publicado: (2004)

Combining MEK and SRC inhibitors for treatment of colorectal cancer demonstrate increased efficacy in vitro but not in vivo
por: Fan, Fan, et al.
Publicado: (2023)

FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma
por: Korphaisarn, Krittiya, et al.
Publicado: (2017)

Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer
por: Varkaris, Andreas, et al.
Publicado: (2019)

Reply: Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly
por: Aparicio, T, et al.
Publicado: (2004)

Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab
por: Liu, Yingmiao, et al.
Publicado: (2013)

Yes-mediated phosphorylation of focal adhesion kinase at tyrosine 861 increases metastatic potential of prostate cancer cells
por: Chatterji, Tanushree, et al.
Publicado: (2015)

A Muti-center, Randomized Phase II Study of Oxaliplatin and S-1 versus Capecitabine and Oxaliplatin in Patients with Metastatic Colorectal Cancer
por: Kim, Jung Han, et al.
Publicado: (2015)

UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer
por: Petrioli, R, et al.
Publicado: (2004)

UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer
por: Alliot, C
Publicado: (2004)

Hepatic Arterial Infusion Chemotherapy With Folfirinox or Oxaliplatin Alone in Metastatic Colorectal Cancer
por: Randrian, Violaine, et al.
Publicado: (2022)

Resistance to MET/VEGFR2 Inhibition by Cabozantinib Is Mediated by YAP/TBX5-Dependent Induction of FGFR1 in Castration-Resistant Prostate Cancer
por: Koinis, Filippos, et al.
Publicado: (2020)

Bevacizumab as a chemoprotectant: reducing oxaliplatin induced hepatic sinusoidal injury
por: Mizrahi, Jonathan D., et al.
Publicado: (2018)

Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer
por: Sarshekeh, Amir Mehrvarz, et al.
Publicado: (2017)

Genomic analysis of exceptional responder to regorafenib in treatment-refractory metastatic rectal cancer: a case report and review of the literature
por: Korphaisarn, Krittiya, et al.
Publicado: (2017)

Survival improvement for patients with metastatic colorectal cancer over twenty years
por: Zeineddine, Fadl A., et al.
Publicado: (2023)

Phase II study of oxaliplatin combined with S-1 and leucovorin (SOL) for Chinese patients with metastatic colorectal cancer
por: Wang, Zhi-Qiang, et al.
Publicado: (2016)

Reply: UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer
por: Francini, G, et al.
Publicado: (2004)

Alternating irinotecan with oxaliplatin combined with UFT plus leucovorin (SCOUT) in metastatic colorectal cancer
por: Sheikh, H Y, et al.
Publicado: (2008)

Combination of oxaliplatin, fluorouracil, and leucovorin in the treatment of fluoropyrimidine-pretreated patients with metastatic colorectal cancer.
por: Lee, J. H., et al.
Publicado: (2001)

Comparison between three oxaliplatin-based regimens with bevacizumab in patients with metastatic colorectal cancer
por: Ohhara, Yoshihito, et al.
Publicado: (2015)

An in silico exploration of combining Interleukin-12 with Oxaliplatin to treat liver-metastatic colorectal cancer
por: Wang, Qing, et al.
Publicado: (2020)

Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancer
por: Arai, Hiroyuki, et al.
Publicado: (2020)

Delayed Oxaliplatin-Related Severe Neurotoxicity in Metastatic Colorectal Cancer: A Case Report
por: Iimura, Yohei, et al.
Publicado: (2023)

An analysis of research biopsy core variability from over 5000 prospectively collected core samples
por: Bhamidipati, Deepak, et al.
Publicado: (2021)

THE ASSOCIATION BETWEEN PREOPERATIVE CHEMOTHERAPY AND THE PREVALENCE OF HEPATIC STEATOSIS IN HEPATECTOMY FOR METASTATIC COLORECTAL CANCER
por: KALIL, Antonio Nocchi, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_sfds3gbebjn05ls0s09hvrdf3q